In solvent-evaporation microsphere processing, RESOMER LR 708 requires adjustment of organic-phase viscosity rather than crystalline solidification rate. The 70:30 L/DL-lactide copolymer remains amorphous under typical solvent-evaporation conditions, which reduces burst release caused by polymer crystallization-induced drug expulsion. The polymer is dissolved in dichloromethane at 10–25% w/w; drug-to-polymer ratios from 1:5 to 1:20 are selected according to target dose. The organic phase is dispersed into aqueous poly(vinyl alcohol) at 0.5–2.0% w/v using a rotor-stator homogenizer at 5,000–15,000 rpm. Emulsion temperature is maintained below 20°C to prevent premature solvent evaporation and droplet coalescence. Particle size shifts from 60–120 µm at 5,000 rpm to 10–40 µm at 12,000 rpm; published data for this specific grade are limited. Solvent removal is controlled to meet ICH Q3C requirements. Dichloromethane is a Class 2 solvent with a permitted daily exposure of 6.0 mg/day, equivalent to 600 ppm in a 10 g/day product intake. Residual solvent is measured by headspace GC according to USP <467>. In vitro release is evaluated in USP apparatus 4 flow-through cells at 37°C; media composition is product-specific. Finished microspheres are lyophilized and filled as a dry powder. Terminal sterilization by gamma irradiation at 25–40 kGy may reduce inherent viscosity through chain scission; therefore, release specification and molar mass retention are verified post-irradiation. The amorphous matrix supports diffusion-controlled release but offers no crystalline reinforcement; the product is restricted to injection through 18–21 G needles and must be suspended in a suitable diluent immediately before administration.

Shear-Induced Molar Mass Loss in Injection Molding of Amorphous 70:30 L/DL-Lactide

Before melt processing, RESOMER LR 708 must be dried below 0.05% w/w residual moisture. Residual moisture above that threshold accelerates hydrolytic backbone cleavage at melt temperatures above 170°C. Vacuum drying at 60–80°C for 4–8 h or dry-air drying to a dew point below -40°C is common. Injection molding of amorphous 70:30 L/DL-lactide screw preforms and small plates uses melt temperatures of 180–220°C; higher temperatures lower melt viscosity but narrow the degradation margin. Molar mass loss measured by size-exclusion chromatography after one heat history can exceed 10% at 220°C if residence time exceeds 10 min; published data for this specific grade are limited. Mold temperatures are held at 20–40°C because the material has no crystallization exotherm to support demolding. Injection pressures of 800–1,500 bar and clamp forces above 50 t on production-scale machines are reported for analogous absorbable PLGA grades. Shear rates in hot runners above 10,000 s⁻¹ may cause localized overheating and yellowing. Finished devices are tested according to ISO 13781:2017 for poly(lactide)-based implants, including chemical composition and inherent viscosity. Biological evaluation follows ISO 10993-1:2018 and ISO 10993-6:2016. Devices are packaged under nitrogen and sterilized by ethylene oxide; the sterilization process is validated under ISO 11135:2014, and residual ethylene oxide limits are set by ISO 10993-7:2008 based on patient exposure. Load-bearing capability is limited by a glass transition near 55–60°C and hydrolytic degradation; the material is not indicated for high-torque cortical screw insertion without metal reinforcement.

Because the 70:30 L/DL-lactide copolymer lacks a crystalline hard segment, monofilament extrusion is restricted to low-tenacity absorbable suture components. Orientation gained during drawing relaxes at temperatures above 50°C, so the fiber cannot maintain knot security under prolonged tissue tension. Extrusion is conducted at melt temperatures below 200°C through a single-screw extruder with L/D ratio 24:1 to 30:1. The polymer is pre-dried to 0.02–0.05% w/w residual moisture. Filaments are quenched in chilled air at 5–10°C and drawn at ratios of 3:1 to 5:1; higher draw ratios induce surface fibrillation. Because the copolymer is amorphous, annealing does not induce secondary crystallization, which limits dimensional stability under body-temperature hydration. Finished filament diameters below 0.50 mm are tested according to USP <861> for diameter, knot-pull strength, and needle attachment. In vivo strength retention is governed by hydrolysis of the DL-lactide segments; published data for this specific grade in suture form are limited. Sterilization by dry-cycle ethylene oxide is preferred over gamma irradiation because irradiation-induced chain scission reduces knot-pull strength. This material is better suited as a component in multilayer tissue-closure systems than as a standalone load-bearing monofilament.

Can 70:30 L/DL-lactide be electrospun into cell-ingrowth matrices without toxic solvent carryover?

For nonwoven scaffold production, electrospinning of RESOMER LR 708 requires solvent systems with sufficient dielectric constant and evaporation rate. Solutions of 10–15% w/w in hexafluoroisopropanol or dichloromethane/dimethylformamide are common. A syringe pump delivers the solution at 0.5–2.0 mL/h to a 20–25 G needle; collector distance is 10–20 cm and applied voltage ranges from 10–25 kV. Fiber diameters between 500 nm and 2 µm are attainable, but solvent residues may remain inside the fiber core after ambient drying. Vacuum drying at 40–50°C for 24–72 h under 0.1 kPa reduces residual solvent; final acceptance is tested by headspace GC. Cytotoxicity must be assessed per ISO 10993-5 because fluorinated solvent carryover can suppress cell attachment. The scaffold lacks crystalline reinforcement, so tensile modulus remains below 10 MPa for high-porosity mats; published data for this specific grade are limited. Crosslinking is not possible without reactive end-group functionalization, so mechanical integrity relies on fiber entanglement and inter-fiber bond points. The scaffold is implanted or seeded under quiescent culture conditions; dynamic bioreactor flow above 1 mL/min through the scaffold can displace fibers unless a support mesh is used. Sterilization by electron beam at 15–25 kGy is applied when ethylene oxide sorption into nanofibers is unacceptable.

When a 70:30 L/DL-lactide coating must release sirolimus over 90 days

In spray-coated implant surfaces, RESOMER LR 708 places different constraints on residual monomer and solvent than microsphere processing. The copolymer is dissolved with sirolimus in chloroform or dichloromethane at a polymer-drug ratio of 75:25 to 50:50 w/w. An ultrasonic spray coater applies the solution in multiple passes; each pass deposits 5–15 µm, and total coating thickness is controlled to avoid delamination. The amorphous polymer has no crystalline phase to impede drug diffusion, so release is influenced mainly by coating thickness and drug loading. In vitro release is tested in phosphate-buffered saline with 0.5% sodium dodecyl sulfate at 37°C; sampling follows USP apparatus 7 for coated stents. Residual chloroform limits under ICH Q3C are 60 ppm as a Class 2 solvent with a permitted daily exposure of 0.6 mg/day. Blood-contact testing follows ISO 10993-4; hemolysis, complement activation, and clotting time are relevant endpoints. Delamination is observed when coating thickness exceeds 15 µm on metallic struts under cyclic deformation; published data for this specific grade are limited. Ethylene oxide sterilization of drug-eluting coatings is constrained by drug thermolability; electron beam or gamma irradiation is used with dose mapping, and drug-content assay after irradiation is mandatory because sirolimus is radiation-sensitive. The low glass transition near 55–60°C requires cold-chain shipping and humidity-controlled packaging.

Solvent-induced precipitation kinetics in N-methyl-2-pyrrolidone depots

At polymer concentrations of 20–40% w/w in N-methyl-2-pyrrolidone, injectable in situ forming depots undergo phase inversion after contact with aqueous tissue fluid. The solvent diffuses outward while water penetrates the polymer solution, forming a solid implant. The initial burst release is controlled by polymer concentration and solvent exchange rate; higher polymer concentration reduces burst but raises solution viscosity. Injection force through 25–30 G needles is a formulation constraint; solutions above 2,000 cP may exceed acceptable manual injection force. The implant formed from the amorphous 70:30 copolymer is typically soft and lacks the rigid shell observed with higher-L-lactide crystalline polymers. Drug release from the depot follows diffusion and polymer degradation; in vitro testing uses USP apparatus 4 or sample-and-separate methods in buffer at 37°C. Residual NMP is subject to ICH Q3C Class 2 guidelines with a permitted daily exposure of 5.3 mg/day, equivalent to 530 ppm for a 10 g/day product intake. Biological evaluation follows ISO 10993-6 for local implantation and ISO 10993-11 for systemic toxicity. Gamma sterilization may not be applicable without stability data because NMP radiolysis can generate acidic species; ethylene oxide is generally incompatible with sealed prefilled syringes. Clinical use is limited to low-load or non-weight-bearing indications because the depot gel cannot withstand mechanical shear.